Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

Ikuo Nakamura; Kais Zakharia; Bubu A. Banini; Dalia S. Mikhail; Tae Hyo Kim; Ju Dong Yang; Catherine D. Moser; Hassan M. Shaleh; Sarah R. Thornburgh; Ian Walters; Lewis R. Roberts

doi:10.1371/journal.pone.0142355

Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

Ikuo Nakamura, Kais Zakharia, Bubu A. Banini, Dalia S. Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D. Moser, Hassan M. Shaleh, Sarah R. Thornburgh, Ian Walters, Lewis R. Roberts

Gastroenterology and Hepatology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Article number	e0142355
Journal	PloS one
Volume	10
Issue number	11
DOIs	https://doi.org/10.1371/journal.pone.0142355
State	Published - Nov 3 2015

ASJC Scopus subject areas

General

Access to Document

10.1371/journal.pone.0142355

Cite this

Nakamura, I., Zakharia, K., Banini, B. A., Mikhail, D. S., Kim, T. H., Yang, J. D., Moser, C. D., Shaleh, H. M., Thornburgh, S. R., Walters, I., & Roberts, L. R. (2015). Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PloS one, 10(11), Article e0142355. https://doi.org/10.1371/journal.pone.0142355

@article{f8f2fe5c415e45aba4c774fc8a3b3dc7,

title = "Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling",

author = "Ikuo Nakamura and Kais Zakharia and Banini, {Bubu A.} and Mikhail, {Dalia S.} and Kim, {Tae Hyo} and Yang, {Ju Dong} and Moser, {Catherine D.} and Shaleh, {Hassan M.} and Thornburgh, {Sarah R.} and Ian Walters and Roberts, {Lewis R.}",

note = "Funding Information: The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh.",

year = "2015",

month = nov,

day = "3",

doi = "10.1371/journal.pone.0142355",

language = "English (US)",

volume = "10",

journal = "PloS one",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "11",

}

TY - JOUR

T1 - Correction

T2 - Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

AU - Nakamura, Ikuo

AU - Zakharia, Kais

AU - Banini, Bubu A.

AU - Mikhail, Dalia S.

AU - Kim, Tae Hyo

AU - Yang, Ju Dong

AU - Moser, Catherine D.

AU - Shaleh, Hassan M.

AU - Thornburgh, Sarah R.

AU - Walters, Ian

AU - Roberts, Lewis R.

N1 - Funding Information: The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh.

PY - 2015/11/3

Y1 - 2015/11/3

UR - http://www.scopus.com/inward/record.url?scp=84951147585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951147585&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0142355

DO - 10.1371/journal.pone.0142355

M3 - Comment/debate

AN - SCOPUS:84951147585

SN - 1932-6203

VL - 10

JO - PloS one

JF - PloS one

IS - 11

M1 - e0142355

ER -

Correction: Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this